Teva Pharmaceutical Industries began trading ordinary shares directly on the New York Stock Exchange (NYSE) on September 14, 2026. This move completes the company’s transition from its now-terminated American Depositary Shares (ADSs) program.
Teva shares will continue to trade under the ticker symbol TEVA on both the NYSE and the Tel Aviv Stock Exchange (TASE).
CEO Richard Francis identified the listing as a milestone in the company’s Pivot to Growth strategy. The transition to direct ordinary shares aims to broaden global investor access and reflects ongoing strategic momentum.